Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Chr. Hansen Holding A/S    CHR   DK0060227585

CHR. HANSEN HOLDING A/S

(CHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Chr. Hansen Holding A/S : Full-year report - Statement of results 2019/20

10/08/2020 | 02:03am EST

Company Announcement No. 23/2020

CEO Mauricio Graber says: “2019/20 was a defining and extremely eventful year for Chr. Hansen. We launched our new 2025 Strategy to become a focused bioscience company and to grow a better world, naturally. We made three acquisitions over a short period of time – HSO Health Care, UAS Laboratories and, most recently, Jennewein – and made an agreement to divest Natural Colors. We are convinced that the long-term value creation from the changes in the portfolio is very attractive, and the changes will be clearly positive to EBITDA margin in the coming year, but will also give a slight short-term negative EBIT margin impact.

On top of all of that, everyone has had to manage through a pandemic which has posed unique challenges. We ended the year with 5% organic growth for the group, well within the guidance we provided at the beginning of the year. Organic growth accelerated in Q4, driven by Health & Nutrition which delivered impressive 18% growth. We also delivered on the earnings side and came in at almost 30% EBIT margin for the full year, and at 34.3% in Q4. Our free cash flow also developed strongly, but this was partly due to capex investments that were delayed during the second half of the year due to COVID-19.

Our three strategic lighthouses – bioprotection, plant health and Bacthera – have progressed well during the year, and we launched a fourth lighthouse, fermented plant bases, at the Capital Markets Day in August 2020, and a fifth lighthouse, human milk oligosaccharides, was announced in September 2020 in connection with the acquisition of Jennewein.

We have a cautious outlook for 2020/21, given the uncertainties that COVID-19 still creates, and it will also be a year where we focus on integrating the acquired businesses and making solid progress on our strategic agenda. We expect an organic growth rate of 5-8%, in line with our long-term ambition, with the highest contribution from Health & Nutrition. We expect an EBIT margin before special items of 27-28%, given the headwinds from currencies, a normalization of the cost base, and the slight headwind from the portfolio changes. At the same time, we remain firmly committed to our long-term ambition of delivering underlying EBIT margin expansion by 2025.”

Chr. Hansen will present the results at a conference call today at 10:00am CEST (9:00am GMT). Dial-in information and a slide deck are available beforehand on https://www.chr-hansen.com/en/investors

Full announcement attached.

For further information please contact:
Martin Riise, Head of Investor Relations, Tel: +45 5339 2250
Annika Stern, Investor Relations Officer, Tel: +45 2399 2382
Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose –  To grow a better world. Naturally. – is at the heart of everything we do.

Attachments

  • Chr. Hansen Company Announcement Q4 2019_20
  • Chr. Hansen Annual Report 2019_20
  • Chr. Hansen Corporate Governance Statement 2019_20
  • Chr. Hansen Remuneration Report 2019_20
  • Chr. Hansen Sustainability Data Sheet 2019_20

© OMX, source OMX

All news about CHR. HANSEN HOLDING A/S
11/18CHR HANSEN A/S : . Hansen Natural Colors inaugurates state-of-the-art R&D center
PU
11/18CHR HANSEN A/S : . Hansen launches next-generation Premium cultures for fresh da..
PU
11/09CHR. HANSEN HOLDING A/S : - Manager's transactions
AQ
11/09CHR HANSEN A/S : Manager's transactions
PU
11/03CHR HANSEN A/S : Manager's transactions
PU
11/03CHR HANSEN A/S : Manager's transactions
AQ
10/30CHR HANSEN A/S : Lise Mortensen assumes responsibility as new CFO
PU
10/30CHR HANSEN A/S : Lise Mortensen assumes responsibility as new CFO
AQ
10/29CHR HANSEN A/S : Notice to convene the Annual General Meeting 2020
PU
10/29CHR HANSEN A/S : Notice to convene the Annual General Meeting 2020
AQ
More news
Financials
Sales 2021 1 127 M 1 340 M 1 340 M
Net income 2021 719 M 855 M 855 M
Net Debt 2021 727 M 864 M 864 M
P/E ratio 2021 118x
Yield 2021 0,17%
Capitalization 79 441 M 12 684 M 94 489 M
EV / Sales 2021 71,1x
EV / Sales 2022 65,9x
Nbr of Employees 3 286
Free-Float 77,9%
Chart CHR. HANSEN HOLDING A/S
Duration : Period :
Chr. Hansen Holding A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHR. HANSEN HOLDING A/S
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 12
Average target price 80,98 €
Last Close Price 603,00 €
Spread / Highest target -82,7%
Spread / Average Target -86,6%
Spread / Lowest Target -89,2%
EPS Revisions
Managers
NameTitle
Mauricio Graber President & Chief Executive Officer
Dominique Reiniche Chairman
Lise Skaarup Mortensen Chief Financial Officer & Executive Vice President
Thomas Schäfer Chief Scientific Officer & Executive VP
Mark Anthony Wilson Independent Director